ReproCELL Acquires The iPS Cell Business Unit Of Stemgent, Inc.

YOKOHAMA, Japan--(BUSINESS WIRE)--ReproCELL (JASDAQ:4978) announced that it will acquire the iPS Cell Business Unit of Stemgent, Inc. This acquisition allows the ReproCELL Group to expand the product lineups of its iPS Cell Business and establish technical advantages, promoting great differentiation.

Stemgent has succeeded in launching many worldwide leading iPS cell research reagent products including mRNA reprogramming kit, xeno-free culture media, and specialty chemicals for cell differentiation, and has established a world-famous, proven and trusted brand in the iPS cell field. Through the acquisition, ReproCELL Group can offer a wide variety of products with full coverage of iPS cell technologies, while also strengthening its sales channel and marketing function in the United States. In addition, the iPS Cell Business Unit of Stemgent has a broad network of academic researchers including a strong scientific advisory board in the United States, while ReproCELL has a wide academic network in Japan with a strong scientific advisory board, as well as its founder Prof. Nakatsuji at Kyoto University and Prof. Nakauchi at the University of Tokyo. The strongest academic network combined in United States and Japan will give us sustainable technical advantages in the iPS cell field.

Help employers find you! Check out all the jobs and post your resume.